Rhumbline Advisers Cytek Biosciences, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 294,525 shares of CTKB stock, worth $1.93 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
294,525
Previous 355,436
17.14%
Holding current value
$1.93 Million
Previous $1.98 Million
17.75%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CTKB
# of Institutions
134Shares Held
71.7MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$112 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$77.1 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$62.2 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$43.6 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$27.3 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $882M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...